Etoposide and cisplatin versus irinotecan and cisplatin as the first‐line therapy for patients with advanced, poorly differentiated gastroenteropancreatic neuroendocrine carcinoma: A randomized phase 2 study

BACKGROUND: Platinum‐based chemotherapy is recommended for the treatment of advanced gastroenteropancreatic neuroendocrine carcinoma (GEP‐NEC). The objective of the current phase 2 study was to compare the efficacy and toxicity between etoposide and cisplatin (EP) and irinotecan and cisplatin (IP) a...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Panpan, Li, Jie, Li, Jian, Zhang, Xiaotian, Zhou, Jun, Wang, Xicheng, Peng, Zhi, Shen, Lin, Lu, Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7186825/
https://www.ncbi.nlm.nih.gov/pubmed/32293725
http://dx.doi.org/10.1002/cncr.32750

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7186825/
https://www.ncbi.nlm.nih.gov/pubmed/32293725
http://dx.doi.org/10.1002/cncr.32750

Ejemplares similares